Phase II Study of RC1416 Injection in COPD

Korábbi kezelés

• A history of autoimmune diseases , or treatment with biologics or systemic immunosuppressants for inflammatory diseases within 8 weeks or 5 half-lives (whichever is longer) prior to signing the informed consent form.
• Currently receiving or planning to start long-term oxygen therapy or mechanical ventilation during the study period.

Más betegség

• A current diagnosis of asthma or a history of asthma.
• Presence of other significant pulmonary diseases except COPD as judged by the Investigator.
• History of malignancy .
• Presence of recurrent, chronic, or other active infections at screening.
• Active hepatitis B, active hepatitis C, positive human immunodeficiency virus (HIV) antibody, or positive Treponema pallidum antibody (TP-Ab).

Egyéb

• Diagnosis of α1-antitrypsin deficiency.
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Aged 40 to 85 years (inclusive) at the time of signing the informed consent form, regardless of gender.
• Body Mass Index (BMI) ≥ 16 kg/m².
• Meets the diagnostic criteria for chronic obstructive pulmonary disease (COPD), and has medical records or relevant documentation indicating a history of COPD for ≥ 12 months at screening.
• Post-bronchodilator ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) < 0.7, and post-bronchodilator FEV1 ≥ 30% and < 80% of the predicted value at screening.
• A current smoker or former smoker with a smoking history of ≥ 10 pack-years, or a history of exposure to other risk factors.
• A score of ≥ 2 on the modified Medical Research Council (mMRC) dyspnea scale at screening.
• Medical records or relevant documentation showing ≥ 2 moderate COPD. exacerbations (AECOPD) or ≥ 1 severe AECOPD within the 12 months prior to screening.
• Medical records or relevant documentation showing receipt of background triple therapy (ICS + LABA + LAMA) for ≥ 3 months prior to randomization.
• A blood eosinophil count ≥ 150/mm³ (0.15×10⁹/L) at screening.